Key Takeaways:
- Sino Biopharm won China approval to trial obesity antibody TQF6422.
- Preclinical data showed in vitro activity over 10 times higher than peers.
- Daiwa raised its price target to HK$7.20 after strong interim results.
Quay lại
Sino Biopharm wins trial nod for obesity antibody with 10x potency
Sino Biopharmaceutical won China approval to trial obesity antibody TQF6422, which showed in vitro activity over 10 times higher than comparable drugs.
The clearance follows Daiwa raising its price target on Sino Biopharm to HK$7.20, citing interim adjusted net profit that far beat forecasts, the brokerage said. TipRanks data shows a consensus Buy rating with a HK$7.80 target on the stock.
TQF6422, a fully human ActRII A/B monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group, is a Class 1 innovative drug cleared by the Center for Drug Evaluation of the National Medical Products Administration. It targets weight management in adults with obesity, or overweight patients with at least one weight-related comorbidity. Preclinical studies showed superior fat reduction and lean mass preservation at lower doses, plus favorable pharmacokinetic and safety profiles. In obese monkey models, combining TQF6422 with semaglutide delivered greater fat reduction and lean mass retention than semaglutide alone, supporting a dual-mechanism approach.
ActRII A/B inhibition blocks signaling pathways that regulate muscle growth and fat accumulation, a mechanism distinct from the GLP-1 class that dominates current weight-loss treatments. The differentiation matters because patients on GLP-1 therapies often lose lean muscle along with fat, a side effect that has drawn scrutiny from physicians. Sino Biopharm is building a diversified weight-management pipeline alongside oral GLP-1 receptor agonists, INHBE siRNA and GLP-1 transdermal patches, broadening its metabolic portfolio beyond its core innovative drug business.
Shares rose 3.8 percent on the news, with short selling of HK$162.61 million at a 20.5 percent ratio. The company's market capitalization stands at HK$85.3 billion, with average daily trading volume of about 99.3 million shares. The obesity market is dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both GLP-1-based therapies that have driven a surge in demand for weight-management drugs. The global obesity drug market is projected to grow into a multi-billion-dollar opportunity as demand for effective treatments expands beyond diabetes, with muscle preservation emerging as a key differentiator.
The approval strengthens Sino Biopharm's pipeline valuation as it competes in the fast-growing obesity market. Investors will watch for Phase 1 data and progress on its oral GLP-1 programs.
This article is for informational purposes only and does not constitute investment advice.
